1. Introduction {#s0005}
===============

Sickle cell disease (SCD) is an autosomal-recessive genetic blood disorder affecting over 100,000 people in the United States ([@bb0160]). SCD is caused by a single base-pair replacement on the allele which encodes for the beta subunit of hemoglobin. SCD ultimately leads to chronic and progressive vascular disease complications which adversely affects the vital organ systems including the heart, lungs, kidney, liver and the brain ([@bb0015], [@bb0080]).

Stroke is one of the leading causes of morbidity and mortality in SCD patients ([@bb0145], [@bb0305], [@bb0350]). Primary stroke events dramatically increase the risk of recurrence ([@bb0225], [@bb0325]). Prior to routine transcranial Doppler screening and use of chronic transfusion therapy in high risk patients, 11% of patients had a major cerebral accident by the age of 20, with a lifetime risk of 40% ([@bb0055], [@bb0250]). However, even with the introduction of this meticulous screening, 39% of SCD patients still experience small white matter strokes by the age of 18 ([@bb0105], [@bb0175]). Although called "silent strokes", these microstrokes are associated with neurocognitive decline as well as an increased risk for overt stroke ([@bb0030], [@bb0120], [@bb0110], [@bb0115], [@bb0270], [@bb0320], [@bb0205], [@bb0375]). Stroke rate is highest between the ages of two and ten([@bb0055], [@bb0250], [@bb0260], [@bb0325]) when metabolic demands of the brain are highest ([@bb0090], [@bb0100]). Therefore, the existing literature on SCD focuses mainly on infant and pediatric subjects, even though almost 95% of SCD patients live into adulthood ([@bb0080], [@bb0285]).

Few studies have explored the structure, function or pathophysiological elements of the neurological consequences of SCD ([@bb0085], [@bb0190], [@bb0310], [@bb0345]). Even fewer studies have explored the SCD brain outside the neonatal and pediatric age group ([@bb0040], [@bb0045], [@bb0355]). Disease progression and accumulation affecting cerebrovascular distribution in SCD patients occurs during the most dynamic periods of brain development. Perturbations during critical periods of neurodevelopment can lead to irreversible damage ([@bb0020], [@bb0150], [@bb0295]) and understanding the structural outcomes in these patients\' brain can help us retrospectively understand injury progression during maturation.

In this current study, we examine measures of brain morphology of clinically asymptomatic SCD patients outside of the pediatric age range in comparison to a racially-matched control group using structural magnetic resonance imaging (MRI). We further use multivariate statistical modeling to find covariates between neuroanatomy, blood counts, hemoglobin subtypes, markers of intravascular hemolysis and vital signs.

2. Subjects and methods {#s0010}
=======================

2.1. Participants {#s0015}
-----------------

A total of 65 subjects were recruited as part of a study on sickle cell disease and neurocognitive outcome at the Children\'s Hospital Los Angeles. The SCD group consisted of 33 clinically asymptomatic SCD patients (mean age = 22.4 ± 8.4; age range = 11.7--41.8; F = 15, M = 18). 27 subjects had hemoglobin SS genotype, three had Sβ~**0**~ genotype and three had SC genotype. All SCD patients received universal access to transcranial Doppler (TCD) screening and transfusions when appropriate. In accordance with current NIH guidelines ([@bb0415]), the Sickle Cell team at Children\'s Hospital Los Angeles recommends hydroxyurea treatment for all children with SS and Sβ~0~-thalasemia after the age of 9 months unless they have been placed on chronic transfusion. The dose is advanced to the maximum tolerated dose according to standard protocol. 20 patients were on monthly transfusions and 13 of the non-transfused patients were prescribed hydroxyurea. No differences were found for total GM or WM volume (corrected for age and sex) in patients on transfusions against medication.

The control group consisted of 32 racially matched control subjects (mean age = 25.0 ± 7.6; age range = 12.3--41.8; F = 22, M = 10). Most control subjects were recruited from first degree relatives of patients. 18 control subjects had hemoglobin AA genotype and 14 had hemoglobin AS genotype (SCD trait). No differences were found for total GM or WM volume (corrected for age and sex) in subjects with hemoglobin AA against AS genotype.

MRI scans, vital signs and blood samples were obtained on the same day for each subject. Exclusion criteria included pregnancy, previous overt stroke, acute chest or pain crisis hospitalization within one month. All subjects were recruited with informed consent or assent; the study was approved by the Institutional Review Board at Children\'s Hospital Los Angeles (CCI\#11-00083). Demographics are reported in [Table 1](#t0005){ref-type="table"}.Table 1Subject demographics. Group averages (Avg) and standard deviations (SD) are given. Group differences were assessed using Student\'s unpaired *t*-tests.Table 1Controls avg (SD)SCD avg (SD)p-ValueN3233Age24.4(7.5)21.3(7.8)0.11Male:Female10:2215:180.24Height166.2 (7.4)164.0 (9.2)0.029[⁎](#tf0005){ref-type="table-fn"}Weight (kg)68.4 (18.7)64.9 (23.2)0.050Body mass index (kg/m^2^)24.7 (6.4)24.2 (8.7)0.77Body surface area (m^2^)1.8 (0.2)1.7 (0.3)0.33Heart rate (min^− 1^)75.2 (19.0)79.9 (12.2)0.24Systolic blood pressure (mm Hg)115.6 (9.6)110.8 (10.9)0.063Diastolic blood pressure (mm Hg)66.8 (9.2)61.2 (7.2)0.0087[⁎](#tf0005){ref-type="table-fn"}O~2~ saturation (%)99.3 (0.9)97.6 (2.3)\< 0.0003[⁎⁎⁎](#tf0015){ref-type="table-fn"}Hemoglobin (g/dL)13.5 (1.4)9.7 (1.6)\< 0.0001[⁎⁎⁎](#tf0015){ref-type="table-fn"}Hematocrit (%)40.0 (3.8)28.2 (4.4)\< 0.0001[⁎⁎⁎](#tf0015){ref-type="table-fn"}White blood cell count (× 10^3^)5.7 (1.7)10.1 (5.0)\< 0.0001[⁎⁎⁎](#tf0015){ref-type="table-fn"}Platelets242.5 (57.0)279.1 (115.3)0.11Mean platelet volume (fL)10.6 (0.9)10.0 (0.7)0.0029[⁎⁎](#tf0010){ref-type="table-fn"}Reticulocytes (%)1.4 (0.6)9.9 (6.2)0.024[⁎⁎](#tf0010){ref-type="table-fn"}Cell-free hemoglobin5.6 (3.8)17.9 (16.8)\< 0.0007[⁎⁎⁎](#tf0015){ref-type="table-fn"}Lactose dehydrogenase517.0 (75.8)973.8 (554.7)\< 0.0001[⁎⁎⁎](#tf0015){ref-type="table-fn"}[^1][^2][^3]

2.2. MRI acquisition and assessment {#s0020}
-----------------------------------

3D T1-weighted images (TE = 3.8 ms TR = 8.3 ms; resolution = 1 mm^3^) and T2-weighted FLAIR images (TE = 2.5 ms; TR = 4.8 ms; resolution = 1.3 × 1.0 × 1.0 mm) were acquired using an 8-channel head coil on a 3 T Philips Achieva (v.3.2.1).

T2-weighted FLAIR images were examined by a neuroradiologist to identify white matter hyperintensities (WMHI). Silent WMHI were classified as 3--5 mm lesions on T2 Flair, observed in two orthogonal planes, that had no known neurological sequelae ([@bb0165]). Since WMHI can be observed in normal children ([@bb0240]) and the prevalence increases with age ([@bb0265]), more than one lesion per decade of age was required to be considered abnormal. 4 of 32 control subjects and 9 of 23 SCD patients were identified with WMHI greater than expected for age. The cumulative volume of tissue with WMHI accounted for \< 0.1 cm^3^ in most individuals (\< 0.01% of total brain volume) and were mostly observed in the parietal and frontal lobes. 1 SCD subject had abnormal MR angiography with severe, bilateral stenosis of the anterior cerebral arteries but all other subjects had normal MR angiograms. No differences were found for total GM or WM volume (corrected for age and sex) in subjects with normal versus abnormal neuroradiological interpretations.

2.3. Image preprocessing and analysis {#s0025}
-------------------------------------

T1-weighted images were processed using BrainSuite ([brainsuite.org](http://brainsuite.org){#ir0010}, v15a) in a semi-automated fashion to classify tissue types, extract and render the surfaces of the inner and pial cortices. Manual correction was performed on cortical boundaries and grey-white boundaries to minimize extraneous inclusion of meninges or exclusion of cortex and to correct occipito-cerebellar boundaries. The brainstem was cut at the base of the cerebellum as seen on the axial slice.

BrainSuite was used for atlas-based registration using the BCI-DNI Brain Atlas ([http://brainsuite.org/svreg_atlas_description/](http://brainsuite.org/svreg_atlas_description){#ir0015}) to label volumetric images and surfaces with two separate segmentation schemes. The first segmentation divided the cerebrum into four lobes and the second sub-divided the brain into 90 regions of interest ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1BCI-DNI Brain Atlas\'s labeled 3D surface and (from left to right) single coronal, axial and sagittal 2D image volume of 2 segmentation schemes: (a) lobes and (b) 90 regions of interest.Fig. 1

Gyral white matter boundaries were defined on the atlas by the two opposing sulcal edges of the gyrus from the coronal view. The sulcal and gyral boundaries were transferred from atlas to subject using BrainSuite ([@bb0185]). BrainSuite performed cortically constrained volumetric brain registration using curvature based alignment of the cortical surface followed by coregistration of subcortical areas using intensity based elastic registration. This was subject to a cortical matching constraint. This resulted in atlas-to-subject matching that was consistently accurate throughout the brain, both at the cortical and subcortical regions.

Average cortical thickness, grey matter (GM) volume, white matter (WM) volume and cortical surface area were calculated for the whole brain and regions of interest (ROIs). Age and sex were controlled for by regressing out age (log-transformed to improve normality) and sex then adding the residuals to the population mean of each measurement. Student *t*-tests were performed on group comparisons and the Benjamini and Hochberg False Discovery Rate (q \< 0.05) was applied to adjust p-values to account for multiple comparisons (SAS, Version 12.1.0, Cary, North Carolina; Version 8.6, Mathworks Inc., Natick, MA). Multivariate regression analysis was performed on the total population. All variables having a univariate p-value \< 0.10 were included as candidates for the stepwise multivariate regression. Variables were only retained in the final model for p \< 0.05.

3. Results {#s0030}
==========

3.1. Sex differences in global brain volumes {#s0035}
--------------------------------------------

No difference in global or regional brain volume was observed between controls with AS (sickle cell trait) or AA hemoglobin, so these data were pooled for all comparisons. [Fig. 2](#f0010){ref-type="fig"} shows age-corrected whole-brain WM volume and GM volume in males and females with SCD compared to racially matched controls. GM volume was slightly lower in both males (p = 0.56) and females (p = 0.27), 1.9% and 3.2% respectively, but this difference did not reach statistical significance. In contrast, WM volume was 7.6% lower in males (p = 0.11) and 8.0% in females (p = 0.020). Using two-way analysis of variance, both sex (p \< 0.0001) and disease state (p = 0.0010) were associated with lower WM volume but the interaction term was not significant (p = 0.93).Fig. 2Mean whole brain GM and WM volume controlled for age grouped by disease status and sex. Error bars indicate 1 standard deviation above and below the mean. WM volume was found to be significantly lower in female SCD patients in comparison to control after adjusting for multiple comparisons (p = 0.020). \*p \< 0.05.Fig. 2

3.2. Global brain morphometric differences {#s0040}
------------------------------------------

Global brain morphometry was calculated for the left and right hemisphere then corrected for age and sex. The two groups were compared using Student *t*-tests and p-values were adjusted for multiple comparisons. SCD patients had significantly lower WM volume in comparison to control subjects by 8.1% (p = 0.0056) in the right hemisphere and 6.8% (p = 0.0068) in the left hemisphere. There were no statistically significant differences found for GM volume ([Table 2](#t0010){ref-type="table"}).Table 2Student *t*-test of the average GM volume, WM volume, cortical thickness and cortical surface area of CTL compared to SCD. All values were corrected by age and sex. p-Values were adjusted for multiple comparisons. WMV: white matter volume; GMV: grey matter volume; CTAvg: average cortical thickness; CSA: cortical surface area; CTL: control subjects; SCD: sickle cell disease patients; R: right; L: left; Avg: average; SD: standard deviation.Table 2MeasurementCTL\
avg (SD)SCD avg (SD)% differenceAdjusted p-valueR. GMV (cm^3^)308.8 (22.5)300.8 (24)2.60.17L. GMV (cm^3^)307.7 (21.5)300 (23.7)2.50.17R. WMV (cm^3^)257.2 (23.6)237.2 (21.9)8.10.0056[⁎⁎](#tf0020){ref-type="table-fn"}L. WMV (cm^3^)255.6 (21.7)238.9 (19.7)6.80.0068[⁎⁎](#tf0020){ref-type="table-fn"}R. CTAvg (mm)3.96 (0.12)4.03 (0.18)− 1.80.097L. CTAvg (mm)3.96 (0.13)4.03 (0.18)− 1.80.097R. CSA (cm^2^)1013.9 (73)979.4 (68.4)3.50.097L. CSA (cm^2^)1010.8 (72.2)979.9 (66.9)3.10.10[^4]

3.3. Covariates of global volumetric data {#s0045}
-----------------------------------------

Stepwise multivariate regression analysis was run on GM and WM volume against vital signs and laboratory data of our sample.

53% of the variability in GM volume could be accounted for by 3 different factors (F(3,57) = 21.38; p \< 0.0001); r^2^ = 0.53). As expected, age (β = − 0.43; p \< 0.0001) and sex (β = 0.52; p \< 0.0001) were the strongest predictors for GM volume. MPV (β = 0.29; p = 0.0026) was also retained in the model.

For WM volume, age was not a significant predictor. Instead, hemoglobin (β = 0.33; p = 0.0036), sex (β = 0.35; p = 0.0017) and MPV (β = 0.27; p = 0.016) were included in the final model accounting for 37% of the variability of WM volume (F(3,58) = 11.30; p \< 0.0001); r^2^ = 0.37).

[Fig. 3](#f0015){ref-type="fig"} shows age and sex corrected GM volume as a function of MPV (r^2^ = 17.1, p = 0.0008) and sex corrected WM volume as a function of hemoglobin (r^2^ = 17.1; p = 0.0006) and MPV (r^2^ = 13.4; p = 0.0035), demonstrating that the predictive value of hemoglobin and MPV are not simply secondary to a group effect.Fig. 3WM volume after controlling for sex as a function of hemoglobin (left) and MPV (middle). GM volume after controlling for age and sex as a function of MPV (right). Solid line shows the linear regression of the data and shaded area delimits the 95% confidence interval. WM: white matter; GM: grey matter; HGB: hemoglobin; MPV: mean platelet volume; CTL: control subjects; SCD: sickle cell disease patients.Fig. 3

3.4. Regional distribution of brain volume changes {#s0050}
--------------------------------------------------

Brain lobe, subcortical and extra-cerebral WM volume controlled for age and sex are shown in [Table 3](#t0015){ref-type="table"} (see [Fig. 1](#f0005){ref-type="fig"}a for reference atlas). WM volume was found to be lower in the right and left frontal (p = 0.035; p = 0.034), parietal (p = 0.035; p = 0.034) and temporal (p = 0.018; p = 0.035) lobes in SCD patients in comparison to controls. The corpus callosum (p = 0.042), right brainstem (p = 0.035) and right cerebellum (p = 0.049) also showed significantly lower WM volume.Table 3Brain lobe, subcortical and extra-cerebral WM volume controlled for age and sex.R: right; L: left; Avg: average; SD: standard deviation.Table 3RegionCTL (cm^3^)\
Avg (SD)SCD (cm^3^)\
Avg (SD)% differenceAdjusted p-valueR frontal74.6 (7.0)68.9 (9.1)8.00.035[⁎](#tf0025){ref-type="table-fn"}L frontal72.8 (7.2)67.1 (7.8)8.30.034[⁎](#tf0025){ref-type="table-fn"}R parietal41.0 (5.0)37.6 (4.4)8.60.035[⁎](#tf0025){ref-type="table-fn"}L parietal47.3 (4.7)43.6 (4.8)8.20.034[⁎](#tf0025){ref-type="table-fn"}R temporal40.2 (4.2)36.5 (3.9)9.70.018[⁎](#tf0025){ref-type="table-fn"}L temporal35.0 (3.4)32.6 (3.3)7.10.035[⁎](#tf0025){ref-type="table-fn"}R occipital21.2 (2.6)20.1 (2.8)5.10.23L occipital22.1 (2.4)21.1 (2.9)4.80.23R subcortex31.2 (3.6)29.1 (3)7.10.087L subcortex29.2 (3.4)27.8 (2.8)5.10.25Corpus callosum6.0 (0.7)5.5 (0.7)8.700.042[⁎](#tf0025){ref-type="table-fn"}R brainstem12.7 (1.5)11.8 (0.9)7.30.035[⁎](#tf0025){ref-type="table-fn"}L brainstem12.6 (1.4)11.9 (1.1)6.30.074R cerebellum18.3 (4.4)16 (2.2)13.30.049[⁎](#tf0025){ref-type="table-fn"}L cerebellum18.3 (4.0)17 (3.1)7.20.25[^5]

No significant regional differences were found for GM volume, average cortical thickness and cortical surface area.

3.5. Group differences in cortical gyri {#s0055}
---------------------------------------

We compared regional WM volume, GM volume, average cortical thickness and cortical surface area group differences for cortical gyri using Student *t*-tests. [Fig. 4](#f0020){ref-type="fig"} show spatial maps of adjusted p-values, controlling for multiple comparisons, on the cortical surface for WM volume (see [Fig. 1](#f0005){ref-type="fig"}b for reference atlas).Fig. 4White matter volume group comparison results, where significant (p \< 0.05), are shown as signed adjusted p-values on the mid-cortical surface. Positive p-values (in blue) indicate CTL \< SCD and negative p-values (in red) indicate SCD \< CTL.Fig. 4

Gyral WM volume was lower in SCD patients in comparison to control subjects diffusely throughout the brain. The bilateral superior frontal gyrus, postcentral gyrus, supramarginal gyrus, angular gyrus, superior parietal gyrus, fusiform gyrus, paracentral lobule, and precuneus were found to have statistically significant lower WM volume. Lateral differences were found in the right middle frontal gyrus, right precentral gyrus, right superior temporal gyrus, left pars triangularis, left middle temporal gyrus and left inferior temporal gyrus where again we saw lower WM volume.

After controlling for multiple comparisons, group differences were not observed in GM volume, average cortical thickness and cortical surface area in cortical gyral measurements.

3.6. Group differences in subcortical structures {#s0060}
------------------------------------------------

Total volume, GM volume and WM volume were controlled for age and sex for subcortical structures. Group differences were not found in the subcortex after multiple comparisons.

4. Discussion {#s0065}
=============

4.1. WM loss in SCD patients {#s0070}
----------------------------

Our most striking finding was the profound global white matter volume loss (6.8--8.1%) in clinically asymptomatic SCD patients in comparison to healthy, racially matched controls ([Table 2](#t0010){ref-type="table"}). Regionally, effects of the disease were greatest in the frontal, parietal and temporal lobes bilaterally, as well as the corpus callosum, right brainstem and right cerebellum. Interestingly the occipital lobe was relatively spared ([Table 3](#t0015){ref-type="table"}).

Effects of SCD on WM tissue has been reported using voxel based morphometry and diffusion tensor imaging (DTI) analysis ([@bb0040], [@bb0045], [@bb0355]). Although numerous studies have reported grey matter loss, only one prior study documented total WM volume loss in SCD patients in comparison to controls ([@bb0345]). Our study is novel in showing regional gyral WM volume loss ([Fig. 4](#f0020){ref-type="fig"}) as well as associations with hemoglobin level and mean platelet volume ([Fig. 3](#f0015){ref-type="fig"}). While most of the brain is affected by the disease, specific regions appear to be spared, revealing a pattern of differential vulnerability.

4.2. WM loss explained by vascular distribution {#s0075}
-----------------------------------------------

The pattern of WM loss ([Fig. 4](#f0020){ref-type="fig"}) generally follows vascular territories and its border zones, with relative sparing of the posterior circulation. The regional WM volume loss in the frontal, parietal and temporal lobes was consistent with patterns of the arterial territories of the middle cerebral artery (MCA) and anterior cerebral artery (ACA). The occipital lobe, which exhibited less shrinkage, is typically supplied by the posterior cerebral artery (PCA) ([@bb0360]) ([Fig. 5](#f0025){ref-type="fig"}). In a study examining 266 patients with SCD from ages 6--19, stroke was reported to primarily involve the frontal lobe, followed by the parietal lobe, subcortical nuclei and temporal lobe, with very few lesions reported in the occipital lobe or cerebellum ([@bb0260]). The pattern of WM loss in SCD patients we found in our current study parallels the pattern of regional vulnerability to stroke in SCD patients in previous literature ([@bb0230], [@bb0260], [@bb0385]).Fig. 5Illustration depicting the vascular territories of the MCA (red), ACA (yellow), and PCA (blue) on a lateral (left) and midline (right) view of the cortical surface. Case courtesy of A.Prof Frank Gaillard, [Radiopaedia.org](http://Radiopaedia.org){#ir0005}, rID: 36099. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 5

Vascular insufficiency as a stimulus for WM loss is further supported by the dominant effect of hemoglobin on whole brain WM volume. Anemic patients raise their cerebral blood flow to maintain oxygen delivery at rest ([@bb0065], [@bb0075]) but this leaves them with a blunted cerebrovascular reserve ([@bb0280]). Although GM is more selectively sensitive than WM to complete occlusion because of its higher metabolic demand ([@bb0025], [@bb0070]), WM is more sensitive to chronic, hypoxia ([@bb0130]). Focal ischemic events, caused by insults like fever, transient hypoxia, or sudden reductions in hemoglobin, can rapidly cause injury to oligodendrocytes ([@bb0255]) and present clinically as white matter hyperintensities (WMH) detected through in-vivo MR imaging ([@bb0060], [@bb0110], [@bb0115], [@bb0290]). Similar findings have been found in murine models whose cerebral blood flow has been altered to induce moderate chronic hypoperfusion through narrowing of the carotid arteries. Differential WM injury and microstrokes were observed along with cognitive decline ([@bb0215], [@bb0335]).

The differential volume loss observed in our study is concordant with the described locations of silent strokes in SCD, as well as WMH found in other disorders (hypertension, sleep apnea) ([@bb0125], [@bb0180], [@bb0235]). Recently, decreased measures of O~2~ saturation have been shown to correlate with compromised WM structure in SCD patients, supporting a role for acute-on-chronic hypoxia in white matter damage ([@bb0195]).

4.3. Phylogenetic predictors of vulnerability {#s0080}
---------------------------------------------

In utero and the first few weeks of life, the fetus is protected from the damaging effects of SCD by fetal hemoglobin. After birth, hemoglobin production is gradually switched to producing abnormal hemoglobin (HbS) over a span of several months ([@bb0140], [@bb0300]). Red blood cells comprised solely of HbS are rigid, oxidatively stressed and have a much shorter lifespan (8 days) than red cells with normal hemoglobin (100 days). Because SCD patients are functionally asplenic after the age of two, damaged sickle red cells are not cleared and often rupture within the vascular system. Over time, vascular endothelia suffer progressive damage because of abnormal mechanical forces and circulating free hemoglobin/heme ([@bb0140], [@bb0300], [@bb0315], [@bb0380]). SCD patients\' disease worsens from accumulation of injury including vascular endothelium damage and hemolysis, ultimately affecting oxygen delivery to the brain ([@bb0035], [@bb0275], [@bb0325], [@bb0395]). Patients\' cerebral blood flow will rise to compensate for the affected oxygen delivery ([@bb0005], [@bb0010], [@bb0165]) to the brain but the anemia and the vascular complications will tend to worsen with time ([@bb0230], [@bb0400]).

The developing brain has a high metabolic demand. Cerebrovascular oxygen consumption peaks around 6--10 years of age before it sharply declines where resting cerebral blood flow drops and lowers cerebral vascular reserve ([@bb0090], [@bb0100]). Coincidentally, stroke risks peak around this time for young patients with SCD ([@bb0055], [@bb0260], [@bb0325]), where presumably, late developing regions would be more plastic and vulnerable to lasting injury caused by acute on chronic ischemia.

Neurodevelopment is asynchronous, where local developmental trajectories are distinct ([@bb0210], [@bb0330], [@bb0340]), and the timing of perturbations will differentially affect outcome ([@bb0170], [@bb0365]). Injury in areas during critical periods of peak development will cause permanent damage while those regions outside its developmental critical period may successfully recover. On a granular level, the white matter areas consistent with sparing in [Fig. 4](#f0020){ref-type="fig"} are primarily located in more evolutionarily conserved brain regions. The few regions spared in our patients were mostly primary sensory cortices---bilateral primary visual cortex, Heschl\'s gyrus and the left precentral gyrus---along with the limbic cortices. These regions are phylogenetically older and may have a more robust blood supply as a result. These regions also develop the earliest and most rapidly ([@bb0155], [@bb0330], [@bb0340], [@bb0405]).

Thus, we postulate that structures that are latest to develop are the first to suffer in response to repeated chronic vascular/hypoxic insults in SCD. Similar neurodegenerative patterns are observed in, Alzheimer\'s and in normal aging. Even some psychiatric disorders, such as schizophrenia, autism and attention deficit disorders, have shown that late-developing brain regions are the first to degenerate later in life ([@bb0135], [@bb0245], [@bb0370]). While our patient population is only in their teens and early adult years, their progressive disease may simply reflect accelerated vascular aging and neurodegeneration. Similar patterns of WM loss and silent stroke have also been observed in hypertension and sleep apnea ([@bb0125], [@bb0180], [@bb0410]).

4.4. GM loss in SCD patients {#s0085}
----------------------------

Previous volumetric SCD studies showed diffuse grey matter volume and cortical thickness deficits ([@bb0045], [@bb0085], [@bb0190], [@bb0200], [@bb0220], [@bb0345]). However, our study was not able to show GM differences (which includes volume, cortical surface area and cortical thickness).

We believe this is because we examined an older patient population than many previous studies. While most other studies included school age children ([@bb0045], [@bb0085], [@bb0190], [@bb0200], [@bb0345]), our study\'s cohort had an average age of 22 years and did not include subjects under the age of 12. One possible explanation is that GM maturation occurs at a different rate in SCD patients, because of stress or other factors associated with their illness, compared with typically developing children ([@bb0085], [@bb0345]). GM volume falls dramatically from childhood to early adulthood as a natural process of synaptic pruning ([@bb0340], [@bb0370], [@bb0405]). The lower GM volume previously found in children with SCD could be attributed to delayed cortical development ([@bb0085], [@bb0345]).

Still, there may be microstructural differences in the cortex that we are not able to detect using our current method. While we only observed lower WM volume, we did see a trend towards higher cortical thickness in SCD patients compared to controls ([Table 2](#t0010){ref-type="table"}). During development, GM volume decreases while WM increases due to myelination. We start to see thickening of gyral white matter into the adjacent GM tissue which leads to decreases in GM volume and cortical thickness ([@bb0210], [@bb0340]). So while our results showed no GM differences, we are hesitant to believe that GM tissue is unaffected in SCD patients.

While age differences are the most likely explanation for our discrepant grey matter findings, differences in our experimental design and methodology could have contributed. Out of the 6 studies showing GM differences in patients with SCD in comparison to controls, only 1 study reported having race-matched controls ([@bb0220]). All studies had different scanner manufacturer and field strength, resolution, and preprocessing pipelines. The current study was well powered to detect WM volume differences so we do not believe we were simply underpowered to detect GM volume differences. Furthermore, our sample size was also larger than 3 of the 6 previous studies mentioned ([@bb0085], [@bb0190], [@bb0200]).

4.5. Why is brain volume correlated with mean platelet volume? {#s0090}
--------------------------------------------------------------

We found a strong positive correlation between MPV and GM and WM volume accounting for 13.4% and 17.1% of the variance respectively, independent of the disease state. Scattergrams ([Fig. 3](#f0015){ref-type="fig"}) do not suggest an outlier or group effect. Elevated MPV is a marker of increased platelet metabolic and enzymatic activity which has been found to be indicative of vascular injury, cardiovascular disease, cerebrovascular disease and inflammatory processes ([@bb0050], [@bb0095], [@bb0390]). Our study shows positive correlations between MPV and brain volume, however, elevated MPV has been shown to be predictive of negative outcome ([@bb0095], [@bb0390]). Our current ability to explain our results are limited and further analysis will be required for clarification.

4.6. Limitations {#s0095}
----------------

Much of our discussion on the relationship between WM volume loss, affected vascular distribution and the timing of perturbations during neurodevelopment in sickle cell disease cannot be confirmed without longitudinal data.

Our current imaging technique and resolution allows us to quantitate only macrostructural brain attributes and limits our ability to investigate the microstructural properties of the brain architecture. While we did not identify systematic changes in GM tissue, there may be subtler disease effects that we were not currently able to detect.

5. Conclusions {#s0100}
==============

In this study, asymptomatic, young-adult SCD patients showed diffuse WM volume differences correlated with low hemoglobin and mean platelet volume, suggesting potential contributions of chronic hypoxia and inflammation. Limited disease effects were found in GM tissue and GM volume negatively correlated with MPV. The pattern of differential WM volume loss suggesting sparing of phylogenetically older brain structures as well as brain regions supplied from the posterior circulation. Longitudinal studies of cerebral abnormalities in SCD patients will provide further insight into disease mechanisms and progression.
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